Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose injectable favipiravir in healthy male subjects
jRCT2071210126Phase 1Active, not recruiting
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of favipiravir in severe fever with thrombocytopenia syndrome (SFTS) (4 cohorts), sponsored by FUJIFILM Toyama Chemical. Primary endpoints: Safety and tolerability - adverse events, Safety and tolerability - laboratory tests and 2 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
favipiravir
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on jRCT2071210126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210126.